Cargando…
The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial
The aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manife...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243094/ https://www.ncbi.nlm.nih.gov/pubmed/34180719 http://dx.doi.org/10.1177/09636897211024942 |
_version_ | 1783715700748058624 |
---|---|
author | Adas, G Cukurova, Z Yasar, K Kart Yilmaz, R Isiksacan, N Kasapoglu, P Yesilbag, Z Koyuncu, ID Karaoz, E |
author_facet | Adas, G Cukurova, Z Yasar, K Kart Yilmaz, R Isiksacan, N Kasapoglu, P Yesilbag, Z Koyuncu, ID Karaoz, E |
author_sort | Adas, G |
collection | PubMed |
description | The aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manifestations were separated as Group 1 (moderate cases, n = 10, treated conventionally), Group 2 (critical cases, n = 10, treated conventionally), and Group 3 (critical cases, n = 10, treated conventionally plus MSCs transplantation therapy of three consecutive doses on treatment days 0, 3, and 6, (as 3 × 10(6) cells/kg, intravenously). The treatment mechanism of action was investigated with evaluation markers of the cytokine storm, via biochemical parameters, levels of proinflammatory and anti-inflammatory cytokines, analyses of tissue regeneration via the levels of growth factors, apoptosis markers, chemokines, matrix metalloproteinases, and granzyme-B, and by the assessment of the immunomodulatory effects via total oxidant/antioxidant status markers and the levels of lymphocyte subsets. In the assessment of the overall mortality rates of all the cases, six patients in Group-2 and three patients in Group-3 died, and there was no loss in Group-1. Proinflammatory cytokines IFNγ, IL-6, IL-17A, IL-2, IL-12, anti-inflammatory cytokines IL-10, IL-13, IL-1ra, and growth factors TGF-β, VEGF, KGF, and NGF levels were found to be significant in Group-3. When Group-2 and Group-3 were compared, serum ferritin, fibrinogen and CRP levels in Group-3 had significantly decreased. CD45 +, CD3 +, CD4 +, CD8 +, CD19 +, HLA-DR +, and CD16 + / CD56 + levels were evaluated. In the statistical comparison of the groups, significance was only determined in respect of neutrophils. The results demonstrated the positive systematic and cellular effects of MSCs application on critically ill COVID-19 patients in a versatile way. This effect plays an important role in curing and reducing mortality in critically ill patients. |
format | Online Article Text |
id | pubmed-8243094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-82430942021-07-13 The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial Adas, G Cukurova, Z Yasar, K Kart Yilmaz, R Isiksacan, N Kasapoglu, P Yesilbag, Z Koyuncu, ID Karaoz, E Cell Transplant Original Article The aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manifestations were separated as Group 1 (moderate cases, n = 10, treated conventionally), Group 2 (critical cases, n = 10, treated conventionally), and Group 3 (critical cases, n = 10, treated conventionally plus MSCs transplantation therapy of three consecutive doses on treatment days 0, 3, and 6, (as 3 × 10(6) cells/kg, intravenously). The treatment mechanism of action was investigated with evaluation markers of the cytokine storm, via biochemical parameters, levels of proinflammatory and anti-inflammatory cytokines, analyses of tissue regeneration via the levels of growth factors, apoptosis markers, chemokines, matrix metalloproteinases, and granzyme-B, and by the assessment of the immunomodulatory effects via total oxidant/antioxidant status markers and the levels of lymphocyte subsets. In the assessment of the overall mortality rates of all the cases, six patients in Group-2 and three patients in Group-3 died, and there was no loss in Group-1. Proinflammatory cytokines IFNγ, IL-6, IL-17A, IL-2, IL-12, anti-inflammatory cytokines IL-10, IL-13, IL-1ra, and growth factors TGF-β, VEGF, KGF, and NGF levels were found to be significant in Group-3. When Group-2 and Group-3 were compared, serum ferritin, fibrinogen and CRP levels in Group-3 had significantly decreased. CD45 +, CD3 +, CD4 +, CD8 +, CD19 +, HLA-DR +, and CD16 + / CD56 + levels were evaluated. In the statistical comparison of the groups, significance was only determined in respect of neutrophils. The results demonstrated the positive systematic and cellular effects of MSCs application on critically ill COVID-19 patients in a versatile way. This effect plays an important role in curing and reducing mortality in critically ill patients. SAGE Publications 2021-06-28 /pmc/articles/PMC8243094/ /pubmed/34180719 http://dx.doi.org/10.1177/09636897211024942 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Adas, G Cukurova, Z Yasar, K Kart Yilmaz, R Isiksacan, N Kasapoglu, P Yesilbag, Z Koyuncu, ID Karaoz, E The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial |
title | The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical
COVID-19 Patients: A Prospective Double Controlled Trial |
title_full | The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical
COVID-19 Patients: A Prospective Double Controlled Trial |
title_fullStr | The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical
COVID-19 Patients: A Prospective Double Controlled Trial |
title_full_unstemmed | The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical
COVID-19 Patients: A Prospective Double Controlled Trial |
title_short | The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical
COVID-19 Patients: A Prospective Double Controlled Trial |
title_sort | systematic effect of mesenchymal stem cell therapy in critical
covid-19 patients: a prospective double controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243094/ https://www.ncbi.nlm.nih.gov/pubmed/34180719 http://dx.doi.org/10.1177/09636897211024942 |
work_keys_str_mv | AT adasg thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT cukurovaz thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT yasarkkart thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT yilmazr thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT isiksacann thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT kasapoglup thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT yesilbagz thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT koyuncuid thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT karaoze thesystematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT adasg systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT cukurovaz systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT yasarkkart systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT yilmazr systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT isiksacann systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT kasapoglup systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT yesilbagz systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT koyuncuid systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial AT karaoze systematiceffectofmesenchymalstemcelltherapyincriticalcovid19patientsaprospectivedoublecontrolledtrial |